Open AccessACE2 Antagonizes VEGFa to Reduce Vascular Permeability During Acute Lung Injury
Author(s) -
Xiuchong Yu,
Qiang Lin,
Qian Xiong,
Zheng Ruan,
Jianhua Zhou,
Zhixiong Lin,
Yijiang Su,
Jian Zheng,
Zhenwei Liu
Publication year - 2016
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000443056
Subject(s) - vascular endothelial growth factor a , vascular permeability , lung , angiotensin converting enzyme 2 , bleomycin , vascular endothelial growth factor , medicine , pharmacology , chemistry , cancer research , vegf receptors , chemotherapy , covid-19 , disease , infectious disease (medical specialty)
Angiotensin converting enzyme 2 (ACE2) treatment suppresses the severity of acute lung injury (ALI), through antagonizing hydrolyzing angiotensin II (AngII) and the ALI-induced apoptosis of pulmonary endothelial cells. Nevertheless, the effects of ACE2 on vessel permeability and its relationship with vascular endothelial growth factor a (VEGFa) remain ill-defined. In the current study, we examined the relationship between ACE2 and VEGFa in ALI model in mice.